Early research (Phase 1)Study completedNCT01364415
What this trial is testing
Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)
Who this might be right for
Neuroendocrine Tumors
Novartis Pharmaceuticals 29